Loading...
| A14917 | Pages: NA | Feb 2022 | 35 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Daratumumab Market
Request Now !Daratumumab (brand name: Darzalex) is a targeted therapy of monoclonal antibody that treats cell surfaces glycoprotein, which is overexpressed on myeloma cells. This glycoprotein is known as cluster of differentiation 38 (CD38). Darzalex is an anti-cancer medication used for the treatment of myeloma. It acts by binding to the CD38 on the red blood cell (RBC). Daratumumab might interfere with the routine testing of clinically significant antibodies. People with pancreative antibody panel tend to cover the presence of any clinically significant antibodies, which, in turn, will negate the daratumumab binding to CD38 on the RBC surface.
Market Scope and Structure Analysis
Report Metric | Details |
Market Size Available for Years | 2021–2030 |
Base Year Considered | 2020 |
Forecast Period | 2021–2030 |
Forecast Unit | Value (USD) |
Segments Covered | Type, Application, Distribution Channel, and Region |
Companies Covered | Johnson and Johnson, Bristol-Myers Squibb Company, Novartis AG, Millennium Pharmaceuticals, Amgen, Inc., Celgene Corporation, Janssen Biotech, Inc., Genzyme Corporation, and Juno Therapeutics |
COVID-19 Impact Analysis
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the daratumumab market.
Top Impacting Factors
Market Trends
New product launches to flourish the market
In 2019, Janssen Biotech Inc., a medical research company under Johnson and Johnson, announced the approval of Darzalex by the Food and Drug Administration to treat newly diagnosed patients with multiple myeloma.
In 2019, Amgen Inc., and American multinational biopharmaceutical company, announced their successful results of their study of phase 3 CANDOR evaluating KYPROLIS (carfilzomib) in combination with dexamethasone and DARZALEX (daratumumab) (KdD).
Key Benefits of the Report
Questions Answered in the Daratumumab Report
Key Market Segments
| Segments | Sub-segments |
|---|---|
| Drug Type |
|
| Application |
|
| Distribution Channel |
|
| Region |
|
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
